Skip to main content
. Author manuscript; available in PMC: 2024 Jan 1.
Published in final edited form as: JCSM Rapid Commun. 2022 Oct 14;6(1):18–25. doi: 10.1002/rco2.72

Table 2.

Six Month Treatment Effects on Body Composition Metrics.

Outcome Measures Risedronate Placebo
n Six Month Six Month Δ n Six Month Six Month Δ p
Body mass (kg) 8 99.3 (95.6, 103.1) −16.3 (−20.0, −12.5) 13 94.7 (91.9, 97.5) −20.9 (−23.7, −18.1) .057
BMI (kg/m2) 8 37.2 (35.8, 38.7) −6.1 (−7.5, −4.6) 13 35.7 (34.7, 36.7) −7.6 (−8.6, −6.6) .095
DXA-Acquired Measures
Total Fat Mass (kg) 8 45.6 (41.8, 49.4) −12.4 (−16.2, −8.6) 13 40.6 (37.9, 43.4) −17.3 (−20.1, −14.6) .048
Percent Fat Mass (%) 8 46.2 (43.1, 49.2) −3.9 (−7.0, −0.8) 13 42.1 (39.8, 44.5) −7.9 (−10.3, −5.6) .045
Total Lean Mass (kg) 8 50.4 (49.1, 51.8) −3.2 (−4.5, −1.9) 13 50.7 (49.7, 51.7) −2.9 (−3.9, −1.9) .745
Appendicular Lean Mass (kg) 8 23.1 (22.0, 24.2) −1.2 (−2.3, −0.1) 13 22.2 (21.4, 23.1) −2.1 (−3.0, −1.2) .202
Appendicular Lean Mass Index (kg/m2) 8 8.6 (8.2, 9.0) −0.4 (−0.8, −0.0) 13 8.3 (8.0, 8.6) −0.8 (−1.1, −0.4) .212
Lean-to-Fat Ratio 8 1.2 (1.0, 1.3) 0.2 (0.1, 0.3) 13 1.3 (1.2, 1.4) 0.4 (0.3, 0.5) .054
CT Acquired Measures
Total Trunk Muscle CSA (cm2) 8 126.9 (121.1, 132.6) −10.2 (−15.9, −4.4) 12 120.6 (115.7, 125.4) −16.5 (−21.3, −11.6) .098
Skeletal Muscle Index (cm2/m2) 8 49.6 (47.3, 51.8) −4.0 (−6.2, −1.7) 12 47.1 (45.2, 49.0) −6.4 (−8.3, −4.5) .098
Total Trunk Muscle Attenuation (HU) 8 35.5 (33.2, 37.9) −3.6 (−5.9, −1.3) 12 36.2 (34.4, 38.1) −2.9 (−4.7, −1.0) .633
Mid-Thigh Muscle CSA (cm2) 8 99.4 (93.9, 104.9) −5.5 (−11.0, 0.1) 12 92.5 (87.8, 97.2) −12.4 (−17.1, −7.7) .067
Mid-Thigh Muscle Attenuation (HU) 8 37.5 (35.0, 39.9) −0.3 (−2.8, 2.2) 12 38.2 (36.1, 40.3) 0.4 (−1.6, 2.5) .638

Group treatment effect and difference estimates from a mixed model using contrast statements at 6 months adjusted for baseline values of each outcome

BMI: Body Mass Index; CSA: Cross-Sectional Area; HU: Hounsfield Units